Bio-Path jumps on FDA nod for cancer therapy clinical trial

Bio Path Holdings

24/08/2021 12:56

** Biotech firm's shares  BPTH.O  jump 30.7% to $7.44 
premarket
    ** Co says U.S. FDA has cleared its application to begin
early-stage trial of experimental therapy, BP1002, in patients
with relapsed acute myeloid leukemia, a type of cancer that
affects blood and bone marrow (https://refini.tv/3sK8Yog)
    ** Trial is expected to be conducted at several leading
cancer centers in U.S., where initially, six evaluable patients
will be treated with BP1002 monotherapy - BPTH
    ** Stock has gained ~63% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))